The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...